BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Insight

Nobody Is the Payer

A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in ...

September 04, 2026 | Analysis

Food, Drug, or Neither

Yesterday was the deadline. Japan's Consumer Affairs Agency has stated that the revised labelling provisions and mandatory Good Manufacturing Practice sta...

September 03, 2026 | Analysis

Making a Drug People Take for Twenty Years

METHOD IN BRIEF Cost-of-goods figures in this article are reconstructions, not disclosures. No company supplied a cost-of-goods figure and none is...

September 01, 2026 | News

The Accidental Gerotherapeutic

METHOD IN BRIEF Outcome evidence in this article is taken from published trial results and approved label language only. No efficacy or outcome claim is s...

August 31, 2026 | Analysis

The Biological Age Business

On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...

August 27, 2026 | Analysis

6 Radiopharmaceutical Programmes and Sites to Watch in APAC

Radioligand therapy is the one modality a region cannot buy its way into late. A vial of lutetium-177 loses half its therapeutic activity in roughly six an...

August 18, 2026 | Analysis

Reading the Register: What Japan's Provision Plans Actually Say

A register, not an approval list Start with the thing that is most often got wrong, including by people who should know better. The Act on the Safety of ...

August 10, 2026 | Analysis

10 Bioprocessing Bottlenecks and How APAC Plants Are Clearing Them

How this list was built Ten bottlenecks were identified from facility interviews, technical sessions at regional bioprocessing conferences and pub...

August 05, 2026 | Analysis

9 AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped

For most of the past decade, the only honest answer to the question of whether AI drug discovery works in Asia-Pacific was that nobody could yet know. The ...

August 04, 2026 | Analysis

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 04, 2026 | Interaction

Advancing Freeze-to-Store Workflows for the Next Era of Biopharmaceutical Manufacturing

As biologics, biosimilars, and advanced cell and gene therapies continue to reshape the Asia-Pacific biopharmaceutical landscape, manufac...

August 03, 2026 | Expert Insight

12 Funding Rounds That Show Where APAC Biotech Capital Is Going

There is a version of this story that lists twelve press releases and calls it analysis. This is not that story. Every round below has already been announc...

July 30, 2026 | News

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

How Is Connected Care Reaching Patients at Home?

At the edge of this trend sit simple connected safety devices that keep patients linked to help. To see how that works in practice, learn more about home e...

July 27, 2026 | News

Stay Connected